Sensars Revolutionizes Neuromodulation Technology
June 12, 2024, 9:36 pm
Sensars, a pioneer in neuromodulation technology, secures EUR 1.1 million in funding to propel the development of its groundbreaking SENSY product. This funding opens doors to advanced solutions for chronic pain relief, offering a ray of hope to millions worldwide. Sensars' innovative approach has garnered support from HTH, a VC firm dedicated to human health, igniting a spark in the realm of pain management solutions.
The launch of the Eurostars project SENSOLE, backed by a EUR 500,000 grant, sets the stage for a revolutionary system designed to monitor and treat gait disabilities and pain in patients with leg neuropathy-induced sensory loss. SENSOLE's fusion of wearable sensors and a neurostimulator paves the way for real-time sensory feedback and personalized treatment through cutting-edge AI software.
Sensars Germany, a branch of Sensars, secures a EUR 600,000 grant from BMBF to test SENSY in amputees, aiming to enhance pain management for this patient group. Collaborating with the University of Heidelberg, this project underscores Sensars' dedication to innovative neuromodulation solutions, pushing boundaries and reshaping the landscape of pain relief.
Venture Kick victory, participation in Venture Leaders Life Sciences, and recognition among the TOP 100 Swiss Startups in 2017 highlight Sensars' journey of perseverance and innovation. Francesco Petrini, Co-Founder and CEO of SensArs, emphasizes the importance of experience and feedback in propelling startups to new heights, showcasing the power of resilience and determination in the face of challenges.
Sensars' high-selective nerve stimulators offer a unique approach to treating neuropathic pain, setting them apart from conventional pain stimulators. With a focus on natural touch and movement sensations, Sensars aims to redefine the standards of pain management, offering a glimmer of hope to those in need.
The launch of the Eurostars project SENSOLE, backed by a EUR 500,000 grant, sets the stage for a revolutionary system designed to monitor and treat gait disabilities and pain in patients with leg neuropathy-induced sensory loss. SENSOLE's fusion of wearable sensors and a neurostimulator paves the way for real-time sensory feedback and personalized treatment through cutting-edge AI software.
Sensars Germany, a branch of Sensars, secures a EUR 600,000 grant from BMBF to test SENSY in amputees, aiming to enhance pain management for this patient group. Collaborating with the University of Heidelberg, this project underscores Sensars' dedication to innovative neuromodulation solutions, pushing boundaries and reshaping the landscape of pain relief.
Venture Kick victory, participation in Venture Leaders Life Sciences, and recognition among the TOP 100 Swiss Startups in 2017 highlight Sensars' journey of perseverance and innovation. Francesco Petrini, Co-Founder and CEO of SensArs, emphasizes the importance of experience and feedback in propelling startups to new heights, showcasing the power of resilience and determination in the face of challenges.
Sensars' high-selective nerve stimulators offer a unique approach to treating neuropathic pain, setting them apart from conventional pain stimulators. With a focus on natural touch and movement sensations, Sensars aims to redefine the standards of pain management, offering a glimmer of hope to those in need.